Second-line chemotherapy for non-small cell lung cancer

Filippo De Marinis, S. De Santis, L. De Petris

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Despite being considered a standard of care, administration of second-line chemotherapy for non-small cell lung cancer is limited to patients in good performance status (ECOG PS 0-1) and to selected patients with PS 2. Drugs currently approved by FDA in this setting are docetaxel, gefitinib, erlotinib and pemetrexed, while in Europe those registered with this indication are only docetaxel and pemetrexed. This short review will focus on the role of pemetrexed, from the controlled phase II trial, to the development of the vitamin supplementation strategy to decrease toxicity, to the large phase III registration trial undertaken vs. the standard docetaxel. Moreover, the huge patient material collected during this latter trial has lead to further analyses to clarify several aspects of second-line treatment, from toxicity to quality of life assessment, to its role in elderly patients and to the direct translation in terms of costs. Finally, we will give a brief overview on current trials, that mainly explore the possibility to raise pemetrexed dose, and thus to increase its activity while maintaining an acceptable toxicity.

Original languageEnglish
JournalAnnals of Oncology
Volume17
Issue numberSUPPL. 5
DOIs
Publication statusPublished - May 2006

Fingerprint

Pemetrexed
docetaxel
Non-Small Cell Lung Carcinoma
Drug Therapy
Standard of Care
Vitamins
Quality of Life
Costs and Cost Analysis
Pharmaceutical Preparations

Keywords

  • Docetaxel
  • NSCLC
  • Pemetrexed
  • Second-line chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Second-line chemotherapy for non-small cell lung cancer. / De Marinis, Filippo; De Santis, S.; De Petris, L.

In: Annals of Oncology, Vol. 17, No. SUPPL. 5, 05.2006.

Research output: Contribution to journalArticle

De Marinis, Filippo ; De Santis, S. ; De Petris, L. / Second-line chemotherapy for non-small cell lung cancer. In: Annals of Oncology. 2006 ; Vol. 17, No. SUPPL. 5.
@article{3aaea4efcb5447bd973230af9728fb72,
title = "Second-line chemotherapy for non-small cell lung cancer",
abstract = "Despite being considered a standard of care, administration of second-line chemotherapy for non-small cell lung cancer is limited to patients in good performance status (ECOG PS 0-1) and to selected patients with PS 2. Drugs currently approved by FDA in this setting are docetaxel, gefitinib, erlotinib and pemetrexed, while in Europe those registered with this indication are only docetaxel and pemetrexed. This short review will focus on the role of pemetrexed, from the controlled phase II trial, to the development of the vitamin supplementation strategy to decrease toxicity, to the large phase III registration trial undertaken vs. the standard docetaxel. Moreover, the huge patient material collected during this latter trial has lead to further analyses to clarify several aspects of second-line treatment, from toxicity to quality of life assessment, to its role in elderly patients and to the direct translation in terms of costs. Finally, we will give a brief overview on current trials, that mainly explore the possibility to raise pemetrexed dose, and thus to increase its activity while maintaining an acceptable toxicity.",
keywords = "Docetaxel, NSCLC, Pemetrexed, Second-line chemotherapy",
author = "{De Marinis}, Filippo and {De Santis}, S. and {De Petris}, L.",
year = "2006",
month = "5",
doi = "10.1093/annonc/mdj954",
language = "English",
volume = "17",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "SUPPL. 5",

}

TY - JOUR

T1 - Second-line chemotherapy for non-small cell lung cancer

AU - De Marinis, Filippo

AU - De Santis, S.

AU - De Petris, L.

PY - 2006/5

Y1 - 2006/5

N2 - Despite being considered a standard of care, administration of second-line chemotherapy for non-small cell lung cancer is limited to patients in good performance status (ECOG PS 0-1) and to selected patients with PS 2. Drugs currently approved by FDA in this setting are docetaxel, gefitinib, erlotinib and pemetrexed, while in Europe those registered with this indication are only docetaxel and pemetrexed. This short review will focus on the role of pemetrexed, from the controlled phase II trial, to the development of the vitamin supplementation strategy to decrease toxicity, to the large phase III registration trial undertaken vs. the standard docetaxel. Moreover, the huge patient material collected during this latter trial has lead to further analyses to clarify several aspects of second-line treatment, from toxicity to quality of life assessment, to its role in elderly patients and to the direct translation in terms of costs. Finally, we will give a brief overview on current trials, that mainly explore the possibility to raise pemetrexed dose, and thus to increase its activity while maintaining an acceptable toxicity.

AB - Despite being considered a standard of care, administration of second-line chemotherapy for non-small cell lung cancer is limited to patients in good performance status (ECOG PS 0-1) and to selected patients with PS 2. Drugs currently approved by FDA in this setting are docetaxel, gefitinib, erlotinib and pemetrexed, while in Europe those registered with this indication are only docetaxel and pemetrexed. This short review will focus on the role of pemetrexed, from the controlled phase II trial, to the development of the vitamin supplementation strategy to decrease toxicity, to the large phase III registration trial undertaken vs. the standard docetaxel. Moreover, the huge patient material collected during this latter trial has lead to further analyses to clarify several aspects of second-line treatment, from toxicity to quality of life assessment, to its role in elderly patients and to the direct translation in terms of costs. Finally, we will give a brief overview on current trials, that mainly explore the possibility to raise pemetrexed dose, and thus to increase its activity while maintaining an acceptable toxicity.

KW - Docetaxel

KW - NSCLC

KW - Pemetrexed

KW - Second-line chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=33745625668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745625668&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdj954

DO - 10.1093/annonc/mdj954

M3 - Article

C2 - 16807467

AN - SCOPUS:33745625668

VL - 17

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - SUPPL. 5

ER -